{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:48:47Z","timestamp":1789908527535,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche Farma S.A."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Rituximab is a standard treatment for non\u2010Hodgkin diffuse large B\u2010cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration\u2010related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety of switching from intravenous to subcutaneous administration of rituximab during first\u2010line induction\/maintenance for DLBCL or FL, focusing on ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients received subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4\u20137 cycles, and\/or every 2\u00a0months maintenance monotherapy for FL for 6\u201312 cycles. The study included 140 patients: DLBCL, <jats:italic>n<\/jats:italic>\u00a0=\u00a029; FL, <jats:italic>n<\/jats:italic>\u00a0=\u00a0111. Ninety\u2010five percent of patients experienced adverse events, reaching grade \u22653 in 38\u00b76% and were serious in 30\u00b70%. AARs occurred in 48\u00b76%, mostly (84\u00b79%) at the injection site, with only 2\u00b71% of patients reaching grade 3. The end\u2010of\u2010induction complete\/unconfirmed complete response rate was 69\u00b76%. After a median follow\u2010up of 33\u00b75\u00a0months, median disease\u2010\/event\u2010\/progression\u2010free and overall survivals were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL\u20105D a good quality\u2010of\u2010life perception at induction\/maintenance end. Therefore, switching to subcutaneous rituximab showed no new safety issues and maintained efficacy with improved satisfaction and quality of life.<\/jats:p>","DOI":"10.1111\/bjh.16227","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T11:52:29Z","timestamp":1569930749000},"page":"661-673","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety of switching from intravenous to subcutaneous rituximab during first\u2010line treatment of patients with non\u2010Hodgkin lymphoma: the Spanish population of the MabRella study"],"prefix":"10.1111","volume":"188","author":[{"given":"Ricardo","family":"Garc\u00eda\u2010Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Department of Haematology Complejo Hospitalario San Mill\u00e1n\u2010San Pedro Logro\u00f1o Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Quero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Hospital Universitario Virgen de la Victoria M\u00e1laga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"P\u00e9rez\u2010Persona","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital de Txagorritxu Vitoria\u2010Gasteiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Domingo\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital General de Granollers Granollers Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"P\u00e9rez\u2010L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitario Cl\u00ednico San Carlos Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Villaescusa\u2010de\u2010la\u2010Rosa","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Mart\u00ednez\u2010Castro","sequence":"additional","affiliation":[{"name":"Department of Haematology Complejo Hospitalario Universitario de Vigo Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Argui\u00f1ano\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital de Navarra Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Parra\u2010Cuadrado","sequence":"additional","affiliation":[{"name":"Medical Department Roche Farma S.A. Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-585X","authenticated-orcid":false,"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[{"name":"Department of Haematology Cl\u00ednica Universidad de Navarra Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"Cock E.","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood.V120.21.1629.1629","article-title":"Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first\u2010line setting: stage 1 results of the phase III SABRINA study (BO22334)","volume":"120","author":"Davies A.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0610-z"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3147-y"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"key":"e_1_2_9_12_1","unstructured":"NCCN(2017)B\u2010cell lymphomas version 7[Online]. Available:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdfAccessed 17 Jan 2018."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2971.2971"},{"key":"e_1_2_9_14_1","first-page":"252","article-title":"Safety of subcutaneous administration of Rituximab during the first\u2010line treatment of patients with non\u2010Hodgkin lymphoma: the MabRella study","volume":"102","author":"Panizo C.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1349906"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.371"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:41:06Z","timestamp":1693687266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/bjh.16227"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16227","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}